Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PXVX 0200

Drug Profile

PXVX 0200

Alternative Names: Cholera vaccine CVD 103-HgR; Cholera vaccine live attenuated - PaxVax; CVD 103-HgR; CVD HgR 103 vaccine; CVD-103; Mutacol; Mutacol-Berna; Orochol; Orochol-Berna; PXVX-0200; Vaxchora

Latest Information Update: 11 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Berna Biotech; Center for Vaccine Development
  • Developer Berna Biotech; Center for Vaccine Development; PaxVax
  • Class Cholera vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cholera

Most Recent Events

  • 04 Jun 2019 Emergent BioSolutions plans to launch PXVX 0200 in other European countries in 2020
  • 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
  • 21 Jul 2017 PaxVax plans a phase IV trial for Cholera in USA (In Childrens) in July 2017 (NCT03220737)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top